News and Events
Upcoming Events
-
October 4, 2008 SWCSNM 11th Annual Fall Educational Meeting, sponsored by NuTech. San Antonio, TX. Click here for additional information or online registration is available by clicking here.
-
March 20-22, 2009 SWCSNM 54th Annual Meeting, Houston, TX
Lexiscan (regadenoson) Now Available From NuTech
Lexiscan (regadenoson) is a new pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. NuTech received the first shipment of Lexiscan from Astellas on June 10, 2008. Please contact one of our pharmacists for prescribing and ordering information. Click here for reimbursement information.
TAC Packaging and Transportation Changes
Review of recent changes in TAC 289.257 "Packaging and Transportation of Radioactive Material".
GE AdreView to Receive FDA Priority Review
GE Healthcare yesterday announced that the U.S. Food and Drug
Administration has designated for priority review the New Drug
Application (NDA) for AdreView [I-123 MIBG], a molecular imaging
agent for the detection of neuroendocrine tumors in pediatric and
adult patients.
According to GE, the FDA also encouraged the company to establish an
expanded access program that would grant physicians limited access
to the novel agent prior to approval.
A priority designation is intended for products or indications that
address unmet medical needs.
GE Healthcare began development of AdreView in 2004, and FDA gave it
orphan-drug designation in December of 2006. GE’s NDA for AdreView
was submitted March 20 and accepted by the FDA on May 20.
(source:
http://www.imagingeconomics.com/news/2008-06-13_01.asp)
Under Investigation
Neoprobe Corp. has begun a multicenter Phase III study of its
radiopharmaceutical agent Lymphoseek in breast cancer and melanoma
patients. Avid Radiopharmaceuticals has started a multicenter Phase
II clinical trial of its F-18-AV-45 molecular-imaging agent to study
whether the agent, used with PET, can image amyloid plaque deposits.
(source:
http://www.nuclearonline.org/newsletter/June08.htm)
